NASDAQ:APLSApellis Pharmaceuticals Stock Price, Forecast & News

Apellis Pharmaceuticals' stock was trading at $27.23 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, APLS shares have increased by 23.7% and is now trading at $33.68. View which stocks have been most impacted by Coronavirus.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Apellis Pharmaceuticals in the last year. There are currently 4 hold ratings, 7 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Apellis Pharmaceuticals.

Apellis Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, July 29th 2020. View our earnings forecast for Apellis Pharmaceuticals.

Apellis Pharmaceuticals Inc (NASDAQ:APLS) announced its quarterly earnings results on Wednesday, April, 29th. The company reported ($2.29) EPS for the quarter, missing the consensus estimate of ($1.38) by $0.91. View Apellis Pharmaceuticals' earnings history.

12 analysts have issued twelve-month target prices for Apellis Pharmaceuticals' shares. Their forecasts range from $29.00 to $86.00. On average, they expect Apellis Pharmaceuticals' share price to reach $52.58 in the next year. This suggests a possible upside of 56.1% from the stock's current price. View analysts' price targets for Apellis Pharmaceuticals.

Media coverage about APLS stock has been trending somewhat negative this week, InfoTrie reports. InfoTrie ranks the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Apellis Pharmaceuticals earned a news impact score of -1.6 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the near future. View the latest news aboutApellis Pharmaceuticals.

Apellis Pharmaceuticals saw a increase in short interest in May. As of May 15th, there was short interest totaling 6,080,000 shares, an increase of 7.8% from the April 30th total of 5,640,000 shares. Based on an average trading volume of 1,030,000 shares, the short-interest ratio is currently 5.9 days. Currently, 10.5% of the company's shares are short sold. View Apellis Pharmaceuticals' Current Options Chain.

Some companies that are related to Apellis Pharmaceuticals include Horizon Therapeutics (HZNP), Mylan (MYL), Dr.Reddy's Laboratories (RDY), Elanco Animal Health (ELAN), Ionis Pharmaceuticals (IONS), ACADIA Pharmaceuticals (ACAD), Perrigo (PRGO), Ascendis Pharma A/S (ASND), Bausch Health Companies (BHC), Jazz Pharmaceuticals (JAZZ), United Therapeutics (UTHR), Reata Pharmaceuticals (RETA), Myokardia (MYOK), Emergent Biosolutions (EBS) and Forty Seven (FTSV). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Apellis Pharmaceuticals investors own include Fate Therapeutics (FATE), Opko Health (OPK), Axsome Therapeutics (AXSM), Corbus Pharmaceuticals (CRBP), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX), AbbVie (ABBV), Amarin (AMRN), Aurinia Pharmaceuticals (AUPH) and Anavex Life Sciences (AVXL).

(APLS) raised $150 million in an initial public offering on Thursday, November 9th 2017. The company issued 10,700,000 shares at a price of $13.00-$15.00 per share. Citigroup, J.P. Morgan and Evercore ISI acted as the underwriters for the IPO.

Apellis Pharmaceuticals trades on the NASDAQ under the ticker symbol "APLS."

Apellis Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Wellington Management Group LLP (13.74%), BlackRock Inc. (7.70%), State Street Corp (3.31%), Cormorant Asset Management LP (3.00%), Jennison Associates LLC (2.77%) and Victory Capital Management Inc. (2.47%). Company insiders that own Apellis Pharmaceuticals stock include Cedric Francois, David O Watson, Morningside Venture Investment, Pascal Deschatelets and Timothy Eugene Sullivan. View institutional ownership trends for Apellis Pharmaceuticals.

APLS stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Cormorant Asset Management LP, Victory Capital Management Inc., Victory Capital Management Inc., Morgan Stanley, Rafferty Asset Management LLC, Citigroup Inc., and Wells Fargo & Company MN. Company insiders that have sold Apellis Pharmaceuticals company stock in the last year include Cedric Francois, and Pascal Deschatelets. View insider buying and selling activity for Apellis Pharmaceuticals.

APLS stock was purchased by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, BlackRock Inc., Jennison Associates LLC, Two Sigma Advisers LP, venBio Partners LLC, Invesco Ltd., Two Sigma Investments LP, and State Street Corp. Company insiders that have bought Apellis Pharmaceuticals stock in the last two years include Morningside Venture Investment, and Timothy Eugene Sullivan. View insider buying and selling activity for Apellis Pharmaceuticals.

Shares of APLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of APLS stock can currently be purchased for approximately $33.68.

Apellis Pharmaceuticals has a market capitalization of $2.54 billion. The company earns $-304,710,000.00 in net income (profit) each year or ($4.64) on an earnings per share basis. Apellis Pharmaceuticals employs 87 workers across the globe.

The official website for Apellis Pharmaceuticals is www.apellis.com.

Apellis Pharmaceuticals' mailing address is 100 FIFTH AVENUE, WALTHAM MA, 02451. The company can be reached via phone at 617-977-5700 or via email at [email protected]